Genentech

Hanmi Pharm shares fell 7.2% to ₩501,000 on Tuesday, trimming part of the 30% rally from the previous day. The move followed an exclusive global licensing agreement with Genentech for obesity candidate HM17321, with a potential total value of up to $2.3 billion and a non‑refundable upfront payment of $190 million. The pullback is being seen as classic profit‑taking after prior gains of about 62% in three weeks and as a result of technical overbought conditions. The KOSPI, meanwhile, ticked up slightly. » Más en de.investing.com

Genentech obtains exclusive rights to HM17321 outside South Korea and will take over development from Phase 2. Hanmi receives an upfront payment of $190 million, milestone-based payments of up to about $2.1 billion, and tiered royalties. HM17321 is currently in a Phase 1 study. » Más en finanzen.net

The Roche subsidiary Genentech is expanding its U.S. production and is investing around $750 million in a new plant in Hillsboro, Oregon. The measure is intended to expand local manufacturing capacity. » Más en finanzen.net